Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pathophysiology

Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients

  1. Giovanni Targher1,
  2. Lorenzo Bertolini1,
  3. Felice Poli2,
  4. Stefano Rodella2,
  5. Luca Scala1,
  6. Roberto Tessari1,
  7. Luciano Zenari1 and
  8. Giancarlo Falezza1
  1. 1Division of Internal Medicine and Diabetes Unity, “Sacro Cuore” Hospital of Negrar, Negrar, Verona, Italy
  2. 2Department of Radiology, “Sacro Cuore” Hospital of Negrar, Negrar, Verona, Italy
  1. Address correspondence and reprint requests to Giovanni Targher, MD, Division of Internal Medicine and Diabetes Unit, Ospedale “Sacro Cuore –don G. Calabria,” Via Sempreboni, 5, 37024 Negrar (VR), Italy. E-mail: targher{at}sacrocuore.it
Diabetes 2005 Dec; 54(12): 3541-3546. https://doi.org/10.2337/diabetes.54.12.3541
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Tables

  • TABLE 1

    Baseline characteristics of the study participants (n = 744)

    VariablesControl subjectsCase subjectsP
    n496248—
    Sex (% men)6262NS*
    Age (years)65 ± 366 ± 4NS*
    BMI (kg/m2)26 ± 329 ± 4<0.001
    Waist circumference (cm)93 ± 13101 ± 14<0.001
    Duration of diabetes (years)13 ± 314 ± 3NS
    Oral hypoglycemic agents (%)61.963.3NS
    Insulin treatment only (%)1214NS
    Current smokers (%)2022NS
    Systolic blood pressure (mmHg)124 ± 13131 ± 15<0.001
    Diastolic blood pressure (mmHg)79 ± 1283 ± 10<0.001
    A1C (%)6.9 ± 0.87.2 ± 0.90.059
    Triglycerides (mmol/l)1.24 ± 0.61.62 ± 0.9<0.001
    HDL cholesterol (mmol/l)1.39 ± 0.31.25 ± 0.4<0.001
    LDL cholesterol (mmol/l)3.29 ± 0.43.27 ± 0.5NS
    AST (units/l)20 ± 1026 ± 12<0.01
    ALT (units/l)23 ± 1233 ± 14<0.001
    GGT (units/l)27 ± 1438 ± 16<0.001
    Microalbuminuria (%)2023NS
    ATP III–defined metabolic syndrome (%)5273<0.001
    NAFLD (%)5694<0.001
    • Data are the means ± SD, unless otherwise indicated. Differences were assessed by the unpaired t test (for normally distributed variables) and by the χ2 test (for categorical variables).

    • *

      * Matched variables.

  • TABLE 2

    Univariate and multivariate logistic regression analyses of factors associated with incident CVD events among type 2 diabetic patients

    VariablesUnivariateMultivariate model 1Multivariate model 2Multivariate model 3
    NAFLD
        OR1.911.91.841.53
        95% CI1.4–2.21.4–2.21.4–2.11.1–1.7
        P values0.0010.0010.0010.02
    ATP III–defined metabolic syndrome
        OR1.641.641.621.58
        95% CI1.3–2.51.3–2.31.3–2.11.3–2
        P values0.0010.0010.0010.01
    Age
        OR1.141.131.131.12
        95% CI1.07–1.161.07–1.141.07–1.141.06–1.14
        P values0.0010.0010.0010.001
    Sex
        OR1.501.481.461.46
        95% CI1.2–21.2–21.2–1.91.2–1.9
        P values0.0010.0010.0010.001
    Diabetes duration
        OR1.08NSNSNS
        95% CI0.8–1.3NSNSNS
        P valuesNSNSNSNS
    A1C
        OR1.511.46NSNS
        95% CI1.1–4.91.02–4.2NSNS
        P values0.020.05NSNS
    Smoking status
        OR1.441.421.401.40
        95% CI1.1–2.01.1–2.01.1–1.91.1–1.9
        P values0.010.010.010.01
    LDL cholesterol
        OR1.18NSNSNS
        95% CI0.9–1.4NSNSNS
        P valuesNSNSNSNS
    GGT
        OR1.421.401.27NS
        95% CI1.1–2.01.1–1.91.05–1.7NS
        P values0.0010.0010.01NS
    Use of medications
        OR1.0NSNSNS
        95% CI0.7–1.2NSNSNS
        P valuesNSNSNSNS
    • Model 1: adjustment for age and sex; model 2: further adjustment for smoking history, diabetes duration, A1C, LDL cholesterol, GGT levels, and use of medications (i.e., hypoglycemic, antihypertensive, lipid-lowering, or antiplatelet drugs); model 3: additional adjustment for the presence of metabolic syndrome or NAFLD (for the first and second variables in the table) or additional adjustment for the presence of metabolic syndrome and NAFLD (for all other variables in the table).

PreviousNext
Back to top

In this Issue

December 2005, 54(12)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients
Giovanni Targher, Lorenzo Bertolini, Felice Poli, Stefano Rodella, Luca Scala, Roberto Tessari, Luciano Zenari, Giancarlo Falezza
Diabetes Dec 2005, 54 (12) 3541-3546; DOI: 10.2337/diabetes.54.12.3541

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients
Giovanni Targher, Lorenzo Bertolini, Felice Poli, Stefano Rodella, Luca Scala, Roberto Tessari, Luciano Zenari, Giancarlo Falezza
Diabetes Dec 2005, 54 (12) 3541-3546; DOI: 10.2337/diabetes.54.12.3541
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Podocyte EGFR Inhibits Autophagy Through Upregulation of Rubicon in Type 2 Diabetic Nephropathy
  • A High-Fat Diet Attenuates AMPK α1 in Adipocytes to Induce Exosome Shedding and Nonalcoholic Fatty Liver Development In Vivo
  • Multinucleated Giant Cells in Adipose Tissue Are Specialized in Adipocyte Degradation
Show more Pathophysiology

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.